Search

Search Constraints

You searched for: Author/Creator Isidori, Alessandro

Search Results

3. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Issue 6 (20th December 2019)

4. Safety of FLT3 inhibitors in patients with acute myeloid leukemia. Issue 9 (2nd September 2021)

8. Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real‐world data. Issue 3 (20th April 2020)

9. Real‐life efficacy and safety of idelalisib in 55 double‐refractory follicular lymphoma patients. (24th August 2022)

10. Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. Issue 4 (7th June 2019)